サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1236106

毛状細胞白血病の世界市場：規模、調査＆予測、治療法（化学療法、標的療法）別、地域別分析、2022-2029年

Global Hairy Cell Leukemia Market Size study & Forecast, by Therapy (Chemotherapy and Targeted Therapy) and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
毛状細胞白血病の世界市場：規模、調査＆予測、治療法（化学療法、標的療法）別、地域別分析、2022-2029年
出版日: 2023年02月27日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

毛状細胞白血病は、骨髄がリンパ球を過剰に産生するがんの一種です。

血液と骨髄の悪性腫瘍です。何年も安定した状態を保ち、感染症を引き起こします。毛状細胞白血病市場は、白血病の有病率の上昇や予測期間における診断率の上昇などの要因から拡大しています。

米国がん協会の2022年データによると、2022年には約60,650件の白血病（全種類）が新たに診断される見込みで、慢性リンパ性白血病（CLL）は約20,160件の新規症例を占めています。また、同資料によると、CLLは新たに診断された白血病のおよそ4分の1を占めています。さらに、2021年のNORDデータによると、約6,000人が毛様細胞白血病に罹患しており、米国では毎年600～800人が新たに診断されています。一方、がん治療の進歩に向けた支出の増加や、市場関係者による研究開発活動の活発化は、市場に有利な機会を生み出しています。しかし、認識不足と限られた医療サービスが、2022-2029年の予測期間を通じて市場成長の妨げとなっています。

世界の毛状細胞白血病市場の調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、ラテンアメリカ、その他の地域です。北米は、高齢者人口の増加、慢性リンパ性白血病の有病率の増加により、収益面で市場を独占しています。一方、北米は、研究開発費の増加や薬剤費の増加などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

市場における最近の動向

  • 2022年8月、AstraZeneca社のCalquence錠が、慢性リンパ性白血病（CLL）、小リンパ性白血病（SLL）、治療歴のある再発または難治性のマントル細胞リンパ腫（MCL）の治療薬としてFDAに承認されました。
  • 2022年5月、ギーセン大学は、毛状細胞白血病患者を対象に、クラドリビン皮下投与1サイクルの有効性と副作用を評価する第2/3相臨床試験を実施しました。

世界の毛状細胞白血病の市場レポート範囲

  • 過去データ：2019-2020-2021年
  • 推計の基準年：2021年
  • 予測期間：2022-2029年
  • レポート範囲：収益予測、企業ランキング、競合情勢、成長要因、動向
  • 地域別範囲：北米、欧州、アジア太平洋地域、ラテンアメリカ、世界のその他地域
  • カスタマイズの範囲：レポートカスタマイズ（最大8名分の作業時間）を無料で提供。国別、地域別、セグメント別範囲の追加・変更。

本調査の目的は、近年における様々な分野・国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢などの詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • 毛状細胞白血病市場、地域別、2019-2029年
    • 毛状細胞白血病の市場、治療法別、2019-2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 世界の毛状細胞白血病市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 本調査の対象となった年
  • 通貨換算レート

第3章 毛状細胞白血病の世界市場力学

  • 毛状細胞白血病の市場インパクト分析（2019-2029年）
    • 市場促進要因
      • 白血病の有病率の上昇
      • 成長する診断率
    • 市場の課題
      • 認識不足と限られた医療サービス
    • 市場機会
      • がん治療の高度化に向けた支出の増加
      • 市場関係者別研究開発活動の活発化

第4章 世界の毛状細胞白血病市場の産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • ソーシャル
    • テクニカル
  • 最高の投資機会
  • 主要成功戦略
  • 業界関係者見通し
  • アナリストの提言と結論

第5章 リスクアセスメントCOVID-19の影響

  • COVID-19が業界に与える全体的な影響についての評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 毛状細胞白血病の世界市場：治療法別

  • マーケットスナップショット
  • 毛状細胞白血病の世界市場：治療法別、業績別- ポテンシャル分析
  • 世界の毛状細胞白血病の治療法別市場推定・予測2019-2029
  • 毛状細胞白血病市場、サブセグメント分析
    • 化学療法
    • 標的療法

第7章 毛状細胞白血病の世界市場：地域別分析

  • 毛状細胞白血病市場、地域別市場スナップショット
  • 北米
    • 米国
      • 療法別の推定・予測、2019年～2029年
    • カナダ
  • 欧州の毛状細胞白血病市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋の毛状細胞白血病市場のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ毛状細胞白血病市場スナップショット
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 世界のその他の地域

第8章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Amgen Inc.
      • 主要な情報
      • 概要
      • 財務（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • AstraZeneca PLC
    • Gilead Sciences
    • F. Hoffmann-La Roche Ltd
    • Astellas Pharma
    • Johnson & Johnson
    • Merck KGaA
    • Biogenomics Limited
    • AbbVie Inc.
    • Pfizer Inc.

第9章 調査のプロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Hairy Cell Leukemia Market, report scope
  • TABLE 2. Global Hairy Cell Leukemia Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Hairy Cell Leukemia Market estimates & forecasts by Therapy 2019-2029 (USD Billion)
  • TABLE 4. Global Hairy Cell Leukemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 5. Global Hairy Cell Leukemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Hairy Cell Leukemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Hairy Cell Leukemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Hairy Cell Leukemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Hairy Cell Leukemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Hairy Cell Leukemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Hairy Cell Leukemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Hairy Cell Leukemia Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Hairy Cell Leukemia Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. U.S. Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 16. U.S. Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. Canada Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. Canada Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. UK Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. UK Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. Germany Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. Germany Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. France Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. France Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. Italy Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. Italy Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Spain Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Spain Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. RoE Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. RoE Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. China Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. China Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. India Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. India Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. Japan Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. Japan Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. South Korea Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. South Korea Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. Australia Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. Australia Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. RoAPAC Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. Brazil Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. Brazil Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Mexico Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Mexico Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. RoLA Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. RoLA Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. Row Hairy Cell Leukemia Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. Row Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Hairy Cell Leukemia Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Hairy Cell Leukemia Market
  • TABLE 69. List of primary sources, used in the study of global Hairy Cell Leukemia Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Hairy Cell Leukemia Market, research methodology
  • FIG 2. Global Hairy Cell Leukemia Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Hairy Cell Leukemia Market, key trends 2021
  • FIG 5. Global Hairy Cell Leukemia Market, growth prospects 2022-2029
  • FIG 6. Global Hairy Cell Leukemia Market, porters 5 force model
  • FIG 7. Global Hairy Cell Leukemia Market, pest analysis
  • FIG 8. Global Hairy Cell Leukemia Market, value chain analysis
  • FIG 9. Global Hairy Cell Leukemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Hairy Cell Leukemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Hairy Cell Leukemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Hairy Cell Leukemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Hairy Cell Leukemia Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Hairy Cell Leukemia Market, regional snapshot 2019 & 2029
  • FIG 15. North America Hairy Cell Leukemia Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Hairy Cell Leukemia Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia Pacific Hairy Cell Leukemia Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Hairy Cell Leukemia Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Hairy Cell Leukemia Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

The global Hairy Cell Leukemia Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Hairy Cell Leukemia is a type of cancer in which the bone marrow produces an excessive number of lymphocytes. It is a blood and bone marrow malignancy. It remains stable for years and creates infections. The Hairy Cell Leukemia market is expanding because of factors such as the rising prevalence of leukemia and growing diagnosis rate in the forecast period.

According to the American Cancer Society's 2022 data, nearly 60,650 new cases of leukemia (all types) are expected to be diagnosed in 2022, with chronic lymphocytic leukemia (CLL) accounting for approximately 20,160 new cases. Furthermore, according to the same source, CLL accounts for roughly one-quarter of newly diagnosed cases of leukemia. Furthermore, according to NORD data for 2021, approximately 6,000 people are affected by hairy cell leukemia, with 600-800 new cases diagnosed in the United States each year. Whereas rising spending towards the advancement of cancer treatment and growing R&D activities by market players create lucrative opportunities for the market. However, a lack of awareness and limited health services hamper the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Hairy Cell Leukemia Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing geriatric population, and growing prevalence of chronic lymphocytic leukemia. Whereas North America is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing demand spending on research and development and growing pharmaceutical spendings.

Major market players included in this report are:

  • Amgen Inc.
  • AstraZeneca PLC
  • Gilead Sciences
  • F. Hoffmann-La Roche Ltd
  • Astellas Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Biogenomics Limited
  • AbbVie Inc.
  • Pfizer Inc.

Recent Developments in the Market:

  • In August 2022, AstraZeneca's Calquence tablet was approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and previously treated relapsed or refractory mantle cell lymphoma (MCL).
  • In May 2022, The University of Giessen conducted a Phase II/III clinical study to evaluate the efficacy and side effects of one cycle of subcutaneous cladribine treatment in patients with hairy cell leukemia.

Global Hairy Cell Leukemia Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Therapy, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:

  • Chemotherapy
  • Targeted Therapy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Hairy Cell Leukemia Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Hairy Cell Leukemia Market, by Therapy, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hairy Cell Leukemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hairy Cell Leukemia Market Dynamics

  • 3.1. Hairy Cell Leukemia Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of leukemia
      • 3.1.1.2. Growing diagnosis rate
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of awareness and limited health services
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising spending towards advancement of cancer treatment
      • 3.1.3.2. Growing R&D activities by market players

Chapter 4. Global Hairy Cell Leukemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Hairy Cell Leukemia Market, by Therapy

  • 6.1. Market Snapshot
  • 6.2. Global Hairy Cell Leukemia Market by Therapy, Performance - Potential Analysis
  • 6.3. Global Hairy Cell Leukemia Market Estimates & Forecasts by Therapy 2019-2029 (USD Billion)
  • 6.4. Hairy Cell Leukemia Market, Sub-Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy

Chapter 7. Global Hairy Cell Leukemia Market, Regional Analysis

  • 7.1. Hairy Cell Leukemia Market, Regional Market Snapshot
  • 7.2. North America Hairy Cell Leukemia Market
    • 7.2.1. U.S. Hairy Cell Leukemia Market
      • 7.2.1.1. Therapy breakdown estimates & forecasts, 2019-2029
    • 7.2.2. Canada Hairy Cell Leukemia Market
  • 7.3. Europe Hairy Cell Leukemia Market Snapshot
    • 7.3.1. U.K. Hairy Cell Leukemia Market
    • 7.3.2. Germany Hairy Cell Leukemia Market
    • 7.3.3. France Hairy Cell Leukemia Market
    • 7.3.4. Spain Hairy Cell Leukemia Market
    • 7.3.5. Italy Hairy Cell Leukemia Market
    • 7.3.6. Rest of Europe Hairy Cell Leukemia Market
  • 7.4. Asia-Pacific Hairy Cell Leukemia Market Snapshot
    • 7.4.1. China Hairy Cell Leukemia Market
    • 7.4.2. India Hairy Cell Leukemia Market
    • 7.4.3. Japan Hairy Cell Leukemia Market
    • 7.4.4. Australia Hairy Cell Leukemia Market
    • 7.4.5. South Korea Hairy Cell Leukemia Market
    • 7.4.6. Rest of Asia Pacific Hairy Cell Leukemia Market
  • 7.5. Latin America Hairy Cell Leukemia Market Snapshot
    • 7.5.1. Brazil Hairy Cell Leukemia Market
    • 7.5.2. Mexico Hairy Cell Leukemia Market
    • 7.5.3. Rest of Latin America Hairy Cell Leukemia Market
  • 7.6. Rest of The World Hairy Cell Leukemia Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
    • 8.2.1. Amgen Inc.
      • 8.2.1.1. Key Information
      • 8.2.1.2. Overview
      • 8.2.1.3. Financial (Subject to Data Availability)
      • 8.2.1.4. Product Summary
      • 8.2.1.5. Recent Developments
    • 8.2.2. AstraZeneca PLC
    • 8.2.3. Gilead Sciences
    • 8.2.4. F. Hoffmann-La Roche Ltd
    • 8.2.5. Astellas Pharma
    • 8.2.6. Johnson & Johnson
    • 8.2.7. Merck KGaA
    • 8.2.8. Biogenomics Limited
    • 8.2.9. AbbVie Inc.
    • 8.2.10. Pfizer Inc.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption